• Cell Death Mechanisms in Liver Disease

  2026-09-27

  Luedde, Kaplowitz, and Schwabe synthesize evidence that hepatocyte death is not merely a marker of liver injury: its mode and context shape inflammation, fibrosis, cirrhosis, and liver cancer. Their review connects clinical biomarkers with cell-death mechanisms and highlights why therapeutic strategies must account for the responding cell type and disease stage.

• Methotrexate Workflows for DHFR and T-Cell Studies

  2026-09-26

  Use Methotrexate to probe DHFR-dependent proliferation, activated T-cell responses, and anti-inflammatory mechanisms—with a concentration-and-time workflow designed to separate growth inhibition from apoptosis. A recent membrane-chromatography comparison also offers practical guidance for choosing permeability assays, while making clear that its findings do not establish Methotrexate-specific pulmonary transport.

• Dexamethasone (DHAP): From Mechanism to Model

  2026-09-25

  Dexamethasone is more than an anti-inflammatory benchmark: its effects vary across immune, neural, stem-cell, and tumor models. This guide connects mechanism to model choice, assay design, and translational interpretation.

• BIIE 0246: Selective Neuropeptide Y Y2 Antagonist

  2026-09-25

  BIIE 0246 is a potent, selective neuropeptide Y Y2 receptor antagonist used to investigate Y2R signaling in neural, gastrointestinal, and feeding-behavior models. Its reported pharmacology supports experimental NPY Y2 receptor inhibition, but it does not establish Y2R as a mechanism in the cited epicardial-adipose arrhythmia study, which identifies NPY signaling through Y1R.

• Imipramine Workflows for Autophagy and Apoptosis

  2026-09-24

  Use Imipramine to build controlled, dose-ranging studies of glioma-cell autophagy and HL-60 apoptosis, while keeping transporter binding potency distinct from cellular response. The workflow combines practical handling guidance with assay controls and a carefully bounded connection to recent ceramide lipidomics in fish nodavirus research.

• Early Adversity Disrupts Innate Defense via Oxytocin

  2026-09-24

  A 2026 mouse study reports that early-life social deprivation weakens defensive responses to looming visual stimuli and links this effect to reduced oxytocin-receptor expression in the superior colliculus. Circuit-level findings and partial behavioral rescue with intranasal oxytocin point to oxytocin signaling as a candidate mechanism, while leaving important questions about timing, specificity, and translation open.

• Removing Pollen Interference in EEM Bioaerosol Analysis

  2026-09-23

  Zhang and colleagues tested how pollen affects fluorescence-based classification of hazardous bioaerosol components and found that fast Fourier transform (FFT) processing improved random-forest accuracy to 89.24%. The study offers a practical signal-processing strategy for reducing spectral interference, while underscoring the need to validate models across sample types and measurement conditions.

• Platanoside, Ferroptosis, and Acute Lung Injury

  2026-09-23

  The reference study identifies an autophagy-dependent mechanism by which platanoside promotes Keap1 degradation, activates the Nrf2/GPX4 antioxidant axis, and suppresses ferroptosis in lipopolysaccharide-induced acute lung injury. Its findings connect molecular regulation of lipid peroxidation with mitochondrial and histological improvements, while also highlighting the need for validation beyond an experimental mouse model.

• Rapamycin (Sirolimus): From mTOR to Translational Insight

  2026-09-22

  Rapamycin (Sirolimus) is more than a potent mTOR perturbation tool: it provides a strategic way to connect pathway inhibition with autophagic flux, immune-cell function, cancer phenotypes, and mitochondrial disease biology. This article translates mechanistic evidence into practical experimental guidance while defining the limits of extrapolating between models.

• MOG (35-55) for EAE Research

  2026-09-22

  MOG (35-55) provides a practical antigenic trigger for reproducible experimental autoimmune encephalomyelitis, from dose-controlled in vitro studies to mouse models of multiple sclerosis. This guide connects peptide handling and EAE workflow design with PARP7–STAT1/STAT2 biology to improve assay interpretation and troubleshooting.

• DiscoveryProbe Bioactive Compound Library Plus Guide

  2026-09-21

  Build mechanism-driven screens that connect purified-protein ligand discovery with cell-based pathway validation. The library’s pre-dissolved, quality-controlled format supports protease inhibitor discovery, apoptosis assays, cancer research, and broader target deconvolution without treating thermal shifts as proof of cellular efficacy.

• Filipin III for Membrane Cholesterol Workflows

  2026-09-21

  Filipin III supports fluorescence-based cholesterol detection in membranes, membrane-fraction assays, and ultrastructural analysis when paired with disciplined controls. This guide translates recent macrophage immunometabolism findings into practical assay designs while clarifying what a cholesterol probe can—and cannot—measure.

• Concanavalin A Targets Conserved Coronavirus N-Glycans

  2026-09-20

  Guo et al. identify conserved high-mannose N-glycosylation sites near the coronavirus spike S2′ cleavage region as a broad antiviral vulnerability. Using complementary fusion, entry, infection, biochemical, and animal models, the study shows that concanavalin A blocks proteolytic spike activation and reduces hCoV-NL63 disease-associated outcomes.

• Cy3 Goat Anti-Human IgG (H+L) Antibody Guide

  2026-09-19

  Use this Cy3 conjugated secondary antibody to visualize human IgG across immunofluorescence, tissue, cytometry, and ELISA workflows. The guide translates orthopoxvirus antibody-mapping research into practical assay design while separating binding readouts from functional neutralization evidence.

• PAD4-IN-2 TFA: Targeting the PAD4–NET Axis

  2026-09-18

  A translational analysis of PAD4-IN-2 TFA, also known as Compound 5i TFA, focusing on tumor-biased uptake, H3cit and NET biology, assay design, immune-context interpretation, and the strategic path from preclinical evidence to better PAD4 research decisions.

8360 records 1/558 page Next 12345 下5页 Last page